Human pharmacologic trials with iohexol.
Injections of iohexol in two series of volunteers, 20 in 1980 and 16 in 1982 are briefly reported. Intravenous injections of iohexol in doses from 125 to 1500 mg I/kg body weight were well tolerated. Iohexol was completely excreted in unchanged form. The results indicate that iohexol may safely be used in clinical trials.
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D002860:Chromium Radioisotopes; D003287:Contrast Media / Q000378:metabolism / Q000633:toxicity*; D004341:Drug Evaluation; D004492:Edetic Acid; D004562:Electrocardiography; D006207:Half-Life; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007463:Iodobenzoates / Q000633:toxicity*; D007472:Iohexol; D007668:Kidney / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D013961:Thyroid Gland / Q000187:drug effects; D014018:Tissue Distribution; D014283:Triiodobenzoic Acids / Q000378:metabolism / Q000633:toxicity*
D002860:Chromium Radioisotopes; D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D007472:Iohexol; D004492:Edetic Acid